10-Q: Relmada Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Relmada Therapeutics reports a net loss for Q1 2025 and provides updates on its strategic review, pipeline diversification, and key upcoming milestones.

Summary

• Relmada Therapeutics, a clinical-stage biotechnology company, reported its financial results for the first quarter of 2025.
• The company incurred a net loss of $17.56 million, or $0.58 per share, compared to a net loss of $21.83 million, or $0.72 per share, for the same period in 2024.
• Research and development expenses decreased to $11.95 million from $13.31 million year-over-year, primarily due to the winding down of REL-1017 studies.
• General and administrative expenses decreased to $6.27 million from $9.68 million year-over-year, mainly due to lower stock-based compensation expense.
• The company's cash and cash equivalents totaled $1.15 million as of March 31, 2025, with short-term investments of $25.91 million.
• The company is projecting insufficient liquidity to sustain its operations through one year following the date that the financial statements are issued, raising substantial doubt about its ability to continue as a going concern.
• Relmada is evaluating financing strategies, including public or private sales of equity or debt, bank loans, or strategic collaborations and licensing agreements.
• The company has paused the Esmethadone (REL-1017) program pending a comprehensive data review.
• Relmada acquired Sepranolone from Asarina Pharma AB and in-licensed NDV-01 from Trigone Pharma Ltd. to diversify its pipeline.
• The REL-P11 psilocybin program was terminated effective May 12, 2025, after a successful Phase 1 study due to the changing regulatory landscape.
• The company expects key milestones over the next 12 months, including data readouts from the NDV-01 Phase 2 NMIBC study and initiation of a Sepranolone clinical trial in PWS.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is diversifying its pipeline and achieving promising initial results with NDV-01, significant concerns remain regarding its financial stability and the paused Esmethadone program. The going concern warning weighs heavily on the overall sentiment.

Positives

• Relmada has diversified its pipeline with the acquisition of Sepranolone and in-licensing of NDV-01.
• The company is focusing on high-value therapeutic areas and prioritizing midto late-stage programs.
• Initial data from the Phase 2 study of NDV-01 showed an 85% Overall Response Rate (ORR) and 83.3% High-Grade Recurrence-Free Survival (HGRFS) in papillary disease at the 3-month assessment.
• The company has a substantial and growing IP portfolio for both Sepranolone and NDV-01.
• The company terminated the REL-P11 psilocybin program to focus on more advanced product candidates.

Negatives

• Relmada reported a net loss of $17.56 million for Q1 2025.
• The company has negative operating cash flows and an accumulated deficit of $658.44 million.
• There is substantial doubt about the company's ability to continue as a going concern due to insufficient liquidity.
• The Esmethadone (REL-1017) program is paused pending a comprehensive data review after disappointing interim analysis results.
• The company received a deficiency letter from Nasdaq for not meeting the minimum bid price requirement.

Risks

• The company's ability to secure additional financing is uncertain.
• The development and commercialization of product candidates are subject to regulatory approvals and market acceptance.
• The company faces risks common to the biotechnology industry, including dependence on collaborative arrangements and protection of proprietary technology.
• The company's stock price may be negatively affected if it fails to regain compliance with Nasdaq listing requirements.
• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to numerous risks and uncertainties.

Future Outlook

Relmada expects key milestones over the next 12 months, including data readouts from the NDV-01 Phase 2 NMIBC study and initiation of a Sepranolone clinical trial in PWS. The company is also evaluating financing strategies to address its liquidity concerns.

Management Comments

• We concluded in our review that the most promising path to create shareholder value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidates, while pausing further work on REL-1017.
• Following a comprehensive evaluation of the Company's business strategy and growth opportunities, management and the Board of Directors have implemented on an enhanced approach aimed at maximizing shareholder value.

Industry Context

Relmada's strategic shift towards pipeline diversification and focus on midto late-stage programs reflects a broader trend in the biotechnology industry to mitigate risk and accelerate market entry. The company's focus on NDV-01 addresses the global BCG shortage for treating NMIBC, a significant unmet medical need.

Comparison to Industry Standards

• Relmada's decision to pause the REL-1017 program after disappointing Phase 3 results aligns with industry practices of cutting losses on unsuccessful clinical trials.
• The company's focus on acquiring and in-licensing assets is a common strategy among small to mid-sized biotech companies to expand their pipeline and leverage existing expertise.
• The initial Phase 2 data for NDV-01, with an 85% Overall Response Rate, appears promising compared to historical response rates for BCG and other NMIBC treatments.
• However, the company's liquidity concerns and need to raise additional capital are a significant challenge, as many biotech companies face difficulties in securing funding, especially in the current market environment.
• Relmada's decision to terminate the psilocybin program reflects the uncertainty surrounding the regulatory landscape for psychedelics, similar to other companies reassessing their strategies in this emerging field.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial instability and the paused Esmethadone program.
• Employees may be affected by potential cost-cutting measures or restructuring efforts.
• Patients may benefit from the development of new therapies for NMIBC, Prader-Willi Syndrome, and Tourette Syndrome.
• Suppliers and creditors face increased risk due to the company's going concern warning.

Next Steps

• The company will continue to develop and commercialize NDV-01 and Sepranolone.
• Relmada will conduct a comprehensive data review of the Esmethadone (REL-1017) program to determine its future.
• The company will seek additional financing to address its liquidity concerns.
• Relmada will monitor the regulatory landscape for psychedelics and assess potential opportunities in the future.
• The company will provide updates on its progress and key milestones in future reports.

Key Dates

Keywords

Relmada Therapeutics, financial results, Q1 2025, NDV-01, Sepranolone, Esmethadone, REL-1017, REL-P11, pipeline diversification, biotechnology, pharmaceutical, clinical trials, NMIBC, Prader-Willi Syndrome, Tourette Syndrome, liquidity, going concern